Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time
The collaboration aims to improve the patient stratification of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
Binyamina, Israel, December 13, 2021 /PRNewswire/ - OncoHost, a global leader in next-generation precision oncology for improved personalized cancer treatments, today announced its partnership with the Heidelberg Biomaterials Bank (BMBH) and Heidelberg A member of Heidelberg Lung Biobank to carry out research cooperation. German Lung Research Center (DZL).
The collaboration involves systematic collection and integration of data to improve patient stratification and identify new biomarkers and therapeutic targets, mainly for non-small cell lung cancer (NSCLC) patients treated by immunotherapy. OncoHost continues to expand its multi-center clinical trial PROPEHTIC. OncoHost will work with Thoraxklinik-Heidelberg's Lung Biobank to collect blood samples, analyze them, and then share the data. The goal is to improve the stratification of lung cancer patients beyond the general biomarkers currently used.
"At baseline and throughout the treatment process, the availability of blood samples is increasingly important for the management of patients with non-small cell lung cancer, especially for the application of targeted therapies, such as immune checkpoint inhibitor therapy," Dr. Thomas Muley, head of lung cancer Said Biobank Heidelberg. "Partnering with OncoHost on this key project will enable us to provide better personalized oncology care for lung cancer patients on a global scale."
PROphet® is the first diagnostic platform that combines proteomics analysis with artificial intelligence to predict patient response to immunotherapy and identify resistance-related processes, providing clinicians with potential combined strategies to overcome treatment resistance. The platform uses high-throughput protein analysis technology to scan more than 7,000 proteins in patients' plasma, combined with proprietary bioinformatics and machine learning-based algorithms to identify proteomics patterns that can better predict patient outcomes. PROphet® has also identified potential drug targets to advance the development of new treatment strategies. Studies have shown that PROphet® is more than 90% accurate in predicting the response of NSCLC and melanoma patients to various therapies.
"The more research collaborations we establish, the deeper our understanding of the cancer biology and host response of cancer patients," said Dr. Ofer Sharon, CEO of OncoHost. "By cooperating with Heidelberg Lung Biobank to share biomaterials and clinical data, our goal is to identify diagnostic, prognostic, and therapeutic biomarkers for NSCLC patients. We look forward to sharing continued positive results in predicting immunotherapy response and providing clinicians with Insights on potential future interventions."
OncoHost combines life science research and advanced machine learning technology to develop personalized strategies to maximize the success rate of cancer treatment. The company uses proprietary proteomics analysis to understand the unique response of patients to treatment and overcome one of the main obstacles in clinical oncology today-resistance to treatment. OncoHost's host response analysis platform (PROphet®) analyzes the proteomic changes in blood samples to monitor the dynamic changes of biological processes induced by the patient (ie, the host) in response to a given cancer treatment. This proteomics feature can highly predict the outcome of individual patients, so as to achieve personalized treatment plans. PROphet® has also identified potential drug targets and promoted the development of new treatment strategies and reasonable combination therapies.
For more information, please visit http://www.oncohost.com.
Follow OncoHost on LinkedIn, Twitter and Facebook.
Media Contact: OncoHost's Lior Feigin FINN partner [email protected] @LiorFeigin +1 929 588 2016 +972 54 282 4503
About the Thoracic Clinic at Heidelberg University Hospital
As one of the largest specialized lung clinics in Europe, our Thorax Clinic has been treating lung and chest diseases for more than 100 years and is a clinic located in Heidelberg University Hospital. Our expert treatment includes all modern diagnostic and treatment procedures, such as lung function, bronchoscopy, imaging and internal robotic assisted surgery. Our internationally recognized hospital department treats some of the most benign and malignant lung diseases nationwide. Our precision oncology is the main area of research activities of the National Cancer Center (NCT). Over the years, Thorax Clinic has established the largest lung biobank in Germany.
Contact: Dr. Thomas Muley Thoraxklinik [email protected]
For more information, please visit http://www.thoraxklinik-heidelberg.de
More news releases on similar topics
Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time